Exceptional sustained long-term complete response to Tepotinib in a <i>MET</i>-amplified advanced intrahepatic biliary tract cancer failing Durvalumab plus Cisplatin and Gemcitabine
Tepotinib showed remarkable efficacy in treating MET-amplified intrahepatic cholangiocarcinoma, underscoring the importance of molecular profiling in BTCs and suggesting a potential new therapeutic approach for this rare cancer subtype.
Authors
- Bernhard Doleschal (ORCID: https://orcid.org/0009-0004-4813-4435)
- Gerald Webersinke (ORCID: https://orcid.org/0000-0001-5654-6190)
- P Kerschner
- Andreas Reichinger (ORCID: https://orcid.org/0000-0002-2835-5634)
- Jonathan Burghofer (ORCID: https://orcid.org/0000-0001-6720-4671)
- Leo Essl
- Holger Rumpold
Institutions
- Johannes Kepler University of Linz (AT)
- Ordensklinikum Linz Barmherzige Schwestern (AT)
- AGO Austria (AT)
Publication Details
- Journal
- The Oncologist
- Published
- 2024-10-02
- DOI
- https://doi.org/10.1093/oncolo/oyae265
- Citations
- 5
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.86